1. Aschenbrenner, Diane S. MS, APRN-BC


* Fingolimod (Gilenya) has been approved for the prevention and mitigation of relapses in relapsing multiple sclerosis.


* It's the first oral drug approved for these purposes.


* Fingolimod carries risks of several serious adverse effects, including bradyarrhythmias, infection, macular edema, respiratory complications, and increases in liver enzyme levels